AbbVie (ABBV) Tops Q3 EPS by 8c, Updates FY EPS Guidance

AbbVie (NYSE: ABBV) reported Q3 EPS of $3.66, $0.08 better than the analyst estimate of $3.58. Revenue for the quarter came in at $14.81 billion versus the consensus estimate of $14.93 billion.

GUIDANCE:

AbbVie sees FY2022 EPS of $13.84-$13.88, versus the consensus of $13.86.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• The Aesthetics Giants Just Confirmed “Ozempic Face” Is Real — and a Newly Public Regenerative Player Wants to Compete for It
• SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
• BlackBerry (BB) Tops Q1 EPS by 1c, Offers Guidance